Department of Food Science, College of Agriculture, National Pingtung University of Science and Technology, Pingtung County, Taiwan.
BMC Complement Altern Med. 2014 Mar 26;14:110. doi: 10.1186/1472-6882-14-110.
Ruscogenin is a major steroid sapogenin in the traditional Chinese herb Ophiopogon japonicus that have multiple bioactivities. Recent studies have demonstrated that ruscogenin is involved in down-regulation of intercellular adhesion molecule-1 (ICAM-1) and nuclear factor-κB (NF-κB) activation in anti-inflammatory pathways. We hypothesized that ruscogenin protects against diabetic nephropathy (DN) by inhibiting NF-κB-mediated inflammatory pathway. To test this hypothesis, the present study was to examine the effects of ruscogenin in rats with streptozotocin (STZ)-induced DN.
Diabetes was induced with STZ (60 mg/kg) by intraperitoneal injection in rats. Two weeks after STZ injection, rats in the treatment group were orally dosed with 0.3, 1.0 or 3.0 mg/kg ruscogenin for 8 weeks. The normal rats were chosen as nondiabetic control group. The rats were sacrificed 10 weeks after induction of diabetes. Changes in renal function-related parameters in plasma and urine were analyzed at the end of the study. Kidneys were isolated for pathology histology, immunohistochemistry, and Western blot analyses.
Ruscogenin administration did not lower the levels of plasma glucose and glycosylated hemoglobin in STZ-diabetic rats. Diabetic rats exhibited renal dysfunction, as evidenced by reduced creatinine clearance, blood urea nitrogen and proteinuria, along with marked elevation in the ratio of kidney weight to body weight, that were reversed by ruscogenin. Ruscogenin treatment was found to markedly improve histological architecture in the diabetic kidney. Renal NF-κB activity, as wells as protein expression and infiltration of macrophages were increased in diabetic kidneys, accompanied by an increase in protein content of intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in kidney tissues. All of the above abnormalities were reversed by ruscogenin treatment, which also decreased the expression of transforming growth factor-β1 and fibronectin in the diabetic kidneys.
Our data demonstrated that ruscogenin suppressed the inflammation and ameliorated the structural and functional abnormalities of the diabetic kidney in rats might be associated with inhibition of NF-κB mediated inflammatory genes expression.
鲁斯可苷元是传统中药麦冬中的一种主要甾体皂甙元,具有多种生物活性。最近的研究表明,鲁斯可苷元参与抗炎途径中细胞间黏附分子-1(ICAM-1)和核因子-κB(NF-κB)的下调。我们假设鲁斯可苷元通过抑制 NF-κB 介导的炎症途径来保护糖尿病肾病(DN)。为了验证这一假设,本研究旨在研究鲁斯可苷元对链脲佐菌素(STZ)诱导的糖尿病肾病大鼠的作用。
大鼠腹腔注射 STZ(60mg/kg)诱导糖尿病。STZ 注射后 2 周,治疗组大鼠给予 0.3、1.0 或 3.0mg/kg 鲁斯可苷元灌胃 8 周。正常大鼠作为非糖尿病对照组。糖尿病诱导 10 周后处死大鼠。研究结束时分析血浆和尿液中与肾功能相关的参数变化。分离肾脏进行病理组织学、免疫组织化学和 Western blot 分析。
鲁斯可苷元给药不能降低 STZ 糖尿病大鼠的血糖和糖化血红蛋白水平。糖尿病大鼠表现出肾功能障碍,表现为肌酐清除率、血尿素氮和蛋白尿降低,同时肾脏重量与体重的比值显著升高,这些变化均被鲁斯可苷元逆转。鲁斯可苷元治疗明显改善了糖尿病肾脏的组织学结构。糖尿病肾脏 NF-κB 活性以及巨噬细胞的蛋白表达和浸润增加,同时肾脏组织中细胞间黏附分子-1 和单核细胞趋化蛋白-1 的蛋白含量增加。鲁斯可苷元治疗可逆转所有上述异常,并降低糖尿病肾脏中转化生长因子-β1 和纤维连接蛋白的表达。
我们的数据表明,鲁斯可苷元抑制炎症并改善大鼠糖尿病肾脏的结构和功能异常,可能与抑制 NF-κB 介导的炎症基因表达有关。